Chengdu Sheng Nuo Biotec 圣诺生物
25 significant filings since 31 May 2026: 2 on regulatory inquiry, 15 on equity incentive and 5 on major holder buying, and 3 other kinds. The latest, on 9 Sep 2026: 关于高级管理人员增持公司股份进展的公告. On 13 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 43.23% to 64.79% from the same period a year earlier.
自 31 May 2026 起有 25 份重大公告：regulatory inquiry 2 份、equity incentive 15 份、major holder buying 5 份，另有 3 类。最新一份（9 Sep 2026）：关于高级管理人员增持公司股份进展的公告。13 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 43.23% 至 64.79%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳,伍云逍 | Unrated | 7 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。